Please upgrade your browser.
A little biotech company, Antigenics (AGEN), announced that Russia has approved its kidney cancer drug, Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world.
New Clinical Data on AVEO Pharmaceuticals' Investigational Triple VEGFR Small Molecule Inhibitor AV-951 to be Presented at AACR Annual Meeting
AV-951 is a novel, highly potent and specific inhibitor of VEGF receptors 1, 2 and 3. Angiogenesis inhibition has demonstrated benefit for patients with a wide range of cancer types, including renal cell carcinoma.
Thallion Pharmaceuticals Inc. completed patient enrollment for the Phase II trial using the new continuous intravenous regimen of TLN-232 (formerly CAP-232) in refractory renal cell carcinoma patients.
Deb Maskens is at the U.S. National Institutes of Health (NIH) in Bethesda, Maryland, for a diagnosis she can't get at home.
Survey confirms dire shortage of specialists is a significant and ongoing issue for patients in all provinces and territories.
Company will implement the free patient assistance programme by partnering with two leading cancer hospitals in Nepal.
Man must wait four months to get his kidney cancer removed. You ask yourself why that happens in modern Australia.
Hot tea can slash your risk of kidney cancer
Victor Ellis was diagnosed last August with medullary renal cell carcinoma, a brutal and largely unfamiliar cancer that originated in his kidney and quickly spread to his lungs, chest cavity, spine and pelvis. Last month, the cancer spread to his heart.
A patient with a solitary brain metastasis from renal cell carcinoma achieved partial response of a cerebral lesion following treatment with sunitinib.
|Powered by NeonCRM|